ACTIVE_NOT_RECRUITING

Semantic Feature Analysis Treatment for Aphasia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This randomized controlled comparative effectiveness study examines manipulation of a key component of an established and efficacious treatment for naming impairments in aphasia, along with cognitive and brain correlates of treatment success. Study participants will be randomly assigned to one of two treatment conditions comparing two different versions of Semantic Feature Analysis treatment. Their performance on standardized and study-specific measures will be used to determine which version of the treatment provides superior outcomes, and measures of automatic language processing and functional brain imaging will also be used to identify the underlying neurocognitive mechanisms associated with positive treatment response.

Official Title

Optimizing and Understanding Semantic Feature Analysis Treatment for Aphasia: A Randomized Controlled Comparative Effectiveness Trial

Quick Facts

Study Start:2020-02-24
Study Completion:2025-08-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT04215952

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 6 months post-onset of aphasia due to unilateral left-hemisphere (LH) stroke
  2. * Independent in activities of daily living (ADLs) necessary to live in community-based housing or available caregiver to assist with ADLs
  3. * Medically stable and able to tolerate intensive treatment schedule (e.g. no uncontrolled seizures, difficulty breathing, frequent migraines)
  4. * English as a first language
  5. * No participation in any other speech-language treatment during this study, including follow-up period
  6. * Sufficient auditory comprehension abilities demonstrated during screening
  7. * Sufficient naming impairment exhibited during screening
  1. * Right Hemisphere stroke
  2. * Neurological disease other than stroke
  3. * Significant psychiatric disorder
  4. * Severe motor speech disorder
  5. * Active substance dependence

Contacts and Locations

Principal Investigator

William D Hula, Ph.D.
PRINCIPAL_INVESTIGATOR
VA Pittsburgh Healthcare System
Patrick J Doyle, Ph.D.
PRINCIPAL_INVESTIGATOR
VA Pittsburgh Healthcare System

Study Locations (Sites)

VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, 15240
United States

Collaborators and Investigators

Sponsor: VA Pittsburgh Healthcare System

  • William D Hula, Ph.D., PRINCIPAL_INVESTIGATOR, VA Pittsburgh Healthcare System
  • Patrick J Doyle, Ph.D., PRINCIPAL_INVESTIGATOR, VA Pittsburgh Healthcare System

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-02-24
Study Completion Date2025-08-30

Study Record Updates

Study Start Date2020-02-24
Study Completion Date2025-08-30

Terms related to this study

Keywords Provided by Researchers

  • Anomia
  • Semantic Feature Analysis

Additional Relevant MeSH Terms

  • Aphasia